During the last session, Bristol-Myers Squibb Co. (NYSE:BMY)’s traded shares were 45.03 million, with the beta value of the company hitting 0.41. At the end of the trading day, the stock’s price was $44.70, reflecting an intraday loss of -8.51% or -$4.16. The 52-week high for the BMY share is $70.93, that puts it down -58.68 from that peak though still a striking -6.44% loss since the share price plummeted to a 52-week low of $47.58. The company’s market capitalization is $90.60B, and the average trade volume was 15.49 million shares over the past three months.
Bristol-Myers Squibb Co. (NYSE:BMY) trade information
Bristol-Myers Squibb Co. (BMY) registered a -8.51% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -8.51% in intraday trading to $44.70, hitting a weekly high. The stock’s 5-day price performance is -7.45%, and it has moved by -14.94% in 30 days. Based on these gigs, the overall price performance for the year is -36.36%.
Bristol-Myers Squibb Co. (BMY) estimates and forecasts
Statistics show that Bristol-Myers Squibb Co. has underperformed its competitors in share price, compared to the industry in which it operates. Bristol-Myers Squibb Co. (BMY) shares have gone down -20.35% during the last six months, with a year-to-date growth rate less than the industry average at -91.88% against 12.90. In the rating firms’ projections, revenue will increase 2.00% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 10.7B as predicted by 17 analyst(s). Meanwhile, a consensus of 15 analyst(s) estimates revenue growth to 10.79B by the end of current fiscal year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 5.14%. While earnings are projected to return -93.26% in 2024, the next five years will return -4.17% per annum.
BMY Dividends
Bristol-Myers Squibb Co. is due to release its next quarterly earnings in May. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance. Investors should also take the other fundamental and operational aspects into account before investing in the stock. The forward dividend ratio for Bristol-Myers Squibb Co. is 2.34, with the dividend yield indicating at 5.23 percent, continuing the trend of increasing dividends in recent years.
